Hydrated silicate minerals on Mars observed by the Mars Reconnaissance Orbiter CRISM instrument.

Phyllosilicates, a class of hydrous mineral first definitively identified on Mars by the OMEGA (Observatoire pour la Mineralogie, L'Eau, les Glaces et l'Activitié) instrument, preserve a record of the interaction of water with rocks on Mars. Global mapping showed that phyllosilicates are widespread but are apparently restricted to ancient terrains and a relatively narrow range of mineralogy (Fe/Mg and Al smectite clays). This was interpreted to indicate that phyllosilicate formation occurred during the Noachian (the earliest geological era of Mars), and that the conditions necessary for phyllosilicate formation (moderate to high pH and high water activity) were specific to surface environments during the earliest era of Mars's history. Here we report results from the Compact Reconnaissance Imaging Spectrometer for Mars (CRISM) of phyllosilicate-rich regions. We expand the diversity of phyllosilicate mineralogy with the identification of kaolinite, chlorite and illite or muscovite, and a new class of hydrated silicate (hydrated silica). We observe diverse Fe/Mg-OH phyllosilicates and find that smectites such as nontronite and saponite are the most common, but chlorites are also present in some locations. Stratigraphic relationships in the Nili Fossae region show olivine-rich materials overlying phyllosilicate-bearing units, indicating the cessation of aqueous alteration before emplacement of the olivine-bearing unit. Hundreds of detections of Fe/Mg phyllosilicate in rims, ejecta and central peaks of craters in the southern highland Noachian cratered terrain indicate excavation of altered crust from depth. We also find phyllosilicate in sedimentary deposits clearly laid by water. These results point to a rich diversity of Noachian environments conducive to habitability.

Two genetic hits (more or less) to cancer.

Most cancers have many chromosomal abnormalities, both in number and in structure, whereas some show only a single aberration. In the era before molecular biology, cancer researchers, studying both human and animal cancers, proposed that a small number of events was needed for carcinogenesis. Evidence from the recent molecular era also indicates that cancers can arise from small numbers of events that affect common cell birth and death processes.

Assessing effects of behavioral intervention on treatment outcomes among patients initiating HIV care: Rationale and design of iENGAGE intervention trial.

During the initial year of HIV diagnosis, while patients are often overwhelmed adjusting to this life changing diagnosis, they must develop self-care behaviors for attending regular medical care visits and antiretroviral therapy (ART) adherence to achieve and sustain viral suppression (VS). Maintaining "HIV adherence" and integrating it into one's daily life is required to sustain VS over time. The HIV care continuum or "treatment cascade," an epidemiological snapshot of the national epidemic in the United States (US), indicates that a minority of persons living with HIV (PLWH) have achieved VS. Little evidence exists regarding the effects of interventions focusing on PLWH newly initiating outpatient HIV care. An intervention that focuses on both retention in care and ART adherence skills delivered during the pivotal first year of HIV care is lacking. To address this, we developed a theory-based intervention evaluated in the Integrating Engagement and Adherence Goals upon Entry (iENGAGE) study, a National Institute of Allergy and Infectious Diseases (NIAID) funded randomized behavioral intervention trial. Here we present the study objectives, design and rationale, as well as the intervention components, targeting rapid and sustained VS through retention in HIV care and ART adherence during participants' first year of HIV care. The primary outcome of the study is 48-week VS (<200 c/mL). The secondary outcomes are retention in care, including HIV visit adherence and visit constancy, as well as ART adherence.

Developmental genetics of neuroblastoma.

Case reports of neuroblastoma revealed that some individuals are genetically predisposed and that this genetic predisposition may have other consequences. According to a mutation model, two classes of individuals could acquire neuroblastoma. One (prezygotic) was a rare class that carried a dominant gene imparting high risk of the tumor. The other (postzygotic) comprised all other individuals, each at low risk. The model related tumor incidence to germinal and somatic mutation rates and thereby carried implications for environmental modification of tumorigenesis and demographic variation in incidence. Case reports also revealed associations of neuroblastoma with congenital defects and a susceptibility to second tumors. Analogy with retinoblastoma and Wilms' tumor of the kidney suggested that these associations could result from action of a neuroblastoma gene or from chromosomal aberration. One known dominantly inherited condition, von Recklinghausen's disease, could dispose to neuroblastoma and create some associations. According to the two-mutation model, neuroblastoma may have been a single recessive gene disorder at the level of the cell. The phenomena of aganglionosis, neuroblastoma in situ, maturation of neuroblastoma to ganglioneuroma, and spontaneous regression suggested that such a neuroblastoma gene interfered with normal developmental processes. The specificities of this gene and of those for von Recklinghausen's disease and pheochromocytoma suggested that the functiof a membrane macromolecule.

Mutation and cancer: a model for human carcinogenesis.

A model for carcinogenesis is presented that provides a framework for understanding the roles of "spontaneous" events, hereditary factors, and environmental agents in human carcinogenesis and for interpreting experimental carcinogenesis. This model incorporates two features: a) transition of target stem cells into cancer cells via an intermediate stage in two irreversible steps, and b) growth and differentiation of normal target and intermediate cells. Cast in mathematical terms, the model can be fitted to age-specific incidence data on human cancers of both children and adults and can illuminate the relative importance of agents that affect transition rates, tissue growth, and tissue differentiation. This is illustrated by application of the model to a) the epidemiology of lung cancer with emphasis on the role of cigarette smoking and b) the epidemiology of breast cancer with emphasis on the roles of hormones, radiation, and hereditary. The nature of the two events and of the intermediate stage is considered in light of hereditary conditions that predispose to cancer in humans. The modes of action of radiation and chemicals in carcinogenesis are discussed, as are predictions based on the model and amenable to experimental verification.

Genetic predisposition to transplacentally induced renal cell carcinomas in the Eker rat.

N-Ethyl-N-nitrosourea-induced transplacental renal carcinogenesis in the rat results primarily in Wilms' tumors, apparently because primitive nephroblasts are the preferred target. Our question is whether N-ethyl-N-nitrosourea-induced mutations in the fetal kidney would increase the number of adult-type renal cell carcinomas in the Eker rat, which is heterozygous for a mutation that predisposes to renal cell carcinoma. Surprisingly, renal cell tumors but no Wilm's tumors began to appear from as early as 1 week after birth. Thus, the inheritance of a renal cell carcinoma mutation determines the specificity of tumor histology even with in utero carcinogenesis.

Altered expression of transforming growth factor-alpha in hereditary rat renal cell carcinoma.

A hereditary form of renal cell carcinoma exists in rats that results from a single gene mutation and is histologically similar to that described in humans. Cell lines derived from these rat tumors were shown to express abundant transforming growth factor-alpha (TGF-alpha) and epidermal growth factor (EGF)-receptor RNA transcripts, but no EGF mRNA. In contrast, normal kidney expressed EGF and EGF-receptor transcripts, but TGF-alpha transcripts were barely detectable. Other kidney epithelial cell lines examined (NRK 52E, MDCK, and LLCPK) were negative for expression of both TGF-alpha and EGF transcripts, but expressed EGF receptors. In addition, the renal cell carcinoma-derived lines secreted TGF-alpha into the media. Immunohistochemistry of normal kidney with a TGF-alpha specific antibody revealed a characteristic pattern of staining of collecting ducts and, to a lesser degree, proximal tubules. In the neoplastic kidney tissue, both the cystic and solid portions of the tumors displayed intense immunoreactivity, indicating that altered expression of this growth factor by the transformed cells occurred in situ. These results suggest that altered TGF-alpha expression is an important aspect of the neoplastic phenotype in rodent as well as human renal cell carcinoma, and support the use of this hereditary rodent tumor model for studying the pathogenesis of this disease.

Hereditary renal cell carcinoma in the rat associated with nonrandom loss of chromosomes 5 and 6.

A spontaneous form of renal cell carcinoma occurs in rats that arises as the result of the inheritance of a mutation in a single autosomal gene. Cytogenetic analysis was performed on seven cell lines and four primary tumor cell preparations derived from this hereditary form of renal cell carcinoma. Banded karyotypes prepared from these seven lines exhibited loss and/or partial deletion of both chromosomes 5 and 6. Translocations involving chromosome 4, resulting in a net loss of genetic material located near the centromere (4q11), were observed in three of the cell lines. Monosomy, translocation, and breakage of chromosome 5 involving band 5q31 and monosomy and partial deletion of chromosome 6 involving band 6q22-q24 were independently observed in primary tumor cells from three of four tumors examined. Monosomy of chromosome 4 was observed in cells from a single tumor. The smallest region of deletion of chromosome 6 common to all the cell lines and tumor cells was 6q24, suggesting the presence of a tumor suppressor gene at this locus. These results indicate that loss of genes located on chromosomes 4, 5, and 6, possibly tumor suppressor gene(s), may be important for tumor development and/or progression in rat renal cell carcinoma and is consistent with the hypothesis that a gene locus on one of these chromosomes may be the site of the original predisposing mutation.

The retinoblastoma-related gene, RB2, maps to human chromosome 16q12 and rat chromosome 19.

A retinoblastoma-related human gene, referred to as RB2, has been cloned based on sequence homology of the E1A-binding domain of the retinoblastoma gene. Structural homology with the retinoblastoma gene suggests a possible function of RB2 as a tumor suppressor gene. In this study, we have mapped this gene to human chromosome 16q12.2 and rat chromosome 19, using fluorescence in situ hybridization and somatic hybrid cell analysis, respectively. Based on known syntenic relationships among human, rat and mouse, the data suggest that the mouse homolog resides on chromosome 8. Deletions of chromosome 16q have been found in several human neoplasias (including breast, ovarian, hepatic, and prostatic cancers) which is in support of an involvement of RB2 in human cancer as a tumor suppressor gene.

Hereditary cancers: from discovery to intervention.

This conference concerned hereditary cancers of the breast, ovary, and colon, which are the common, often fatal, cancers with the greatest heritability in their causation. Four genes whose mutations impart dominantly heritable predisposition to one or more of these cancers have been cloned and one more has been mapped. The most molecular details are known for colon cancer. The APC gene of familial polyposis coli leads to the accumulation of numerous polyps, but the probability of transformation of the latter to cancer is low. This provides the opportunity to monitor putative preventive measures with an intermediate end point. In hereditary nonpolyposis colon cancer, transformation of the polyp to cancer is accelerated by an inherited mutation in either of two DNA mismatch repair genes. The discovery of an intermediate end point could be very helpful for breast cancer. Testing persons at risk for predisposing mutations depends heavily on the availability of promising measures for prevention or treatment.

CpG DNA functions as an effective adjuvant for the induction of immune responses in aged mice.

The present studies demonstrate that the immunization of aged mice with Diphtheria toxoid in formulations containing unmethylated immunostimulatory CpG motifs, promotes the successful development of immune responses that are qualitatively and quantitatively comparable to those induced in young animals vaccinated in a similar manner. Aged mice given vaccines containing CpG oligodeoxynucleotides (ODNs) expressed primary and secondary systemic humoral immune responses having isotype profiles consistent with an enhancement in Th-1 type immunity. The ability to generate common mucosal immunity was also restored in aged animals given CpG ODN-containing vaccines. Dendritic cells (DCs) were determined to represent one of the cellular targets of CpG ODN activities in aged mice since restoration of immune function was observed when DCs from aged donors were pulsed with antigen and CpG ODNs, prior to injection into syngeneic young adult or aged recipients. Interestingly, antigen-pulsed DCs from young donors were fully capable of stimulating immune responses following their injection into syngeneic young adult or aged hosts, without a need for exposure to CpG ODNs. Although the mechanism(s) by which CpG DNA exerts its beneficial adjuvant effects on the aged immune system remains unclear, our findings suggest that the incorporation of CpG ODNs into vaccine formulations provided to the aged could prove useful in the development of more effective vaccines for the elderly.

Hereditary cancer: two hits revisited.

According to a "two-hit" model, dominantly inherited predisposition to cancer entails a germline mutation, while tumorigenesis requires a second, somatic, mutation. Non-hereditary cancer of the same type requires the same two hits, but both are somatic. The original tumor used in this model, retinoblastoma, involves mutation or loss of both are somatic. The original tumor used in this model, retinoblastoma, involves mutation or loss of both copies of the RB1 tumor-suppressor gene in both hereditary and non-hereditary forms. In fact, most dominantly inherited cancers show this relationship. New dominantly inherited cancers show this relationship. New questions have arisen, however. When a tumor-suppressor gene is ubiquitously expressed, why is there any specificity of tumor predilection? In some instances, it is clear that two hits produce only a benign precursor lesion and that other genetic events are necessary. As the number of necessary events increase, the impact of the germline mutation diminishes. The number of events is least for embryonal tumors, and relatively small for certain sarcomas. Stem-cell proliferation evidently plays a key role early in carcinogenesis. In some tissues it is physiological, as in embryonic development and in certain tissues in adolescence. In adult renewal tissues, the sites of the common carcinomas, mutation may be necessary to impair the control of switching between renewal and replicative cell divisions; the APC gene may be the target of such a mutation.

Hereditary predisposition to cancer.

Both hereditary and environmental factors influence the risk of cancer. Four risk categories, or oncodemes, can exist for a particular kind of cancer, depending upon the presence of neither, one, or both factors: (1) spontaneous, or background; (2) hereditary; (3) environmental; (4) interactive. In the second, mutation imparts a high relative risk, but a generally low attributable risk; in the fourth, the opposite obtains. The second oncodeme contains genes that are also important for the non-hereditary forms of the same cancer. Probably all forms of cancer exist in a dominantly heritable form. Most of the genes are tumor suppressors, although a few are oncogenes or DNA repair genes. The mutations are in most, if not all cases, maintained in a population by an equilibrium between mutation and selection. Most of the cloned genes are expressed widely among tissues, yet there is typically some tumor specificity. Somatic mutations in second alleles at the relevant loci are necessary, but generally not sufficient for carcinogenesis, although they, in some instances, lead to the formation of benign precursor lesions. Further events are necessary for carcinogenesis. This is particularly true for carcinomas. The benign lesions appear to involve an increase in number of long-lived cells that can accumulate other mutations. For some tumors, physiologic events, such as tissue growth at puberty or proliferation of embryonic stem cells, may produce this effect. Mutations of DNA mismatch repair genes underscore the effect that changes in somatic mutation rates can have, especially in the risk for multi-event carcinomas. Conversely, these are the tumors that offer the greatest opportunity for prevention.

Cancer genes in man.

We may conclude, from all of these considerations, that the burden of cancer falls unequally upon a population of individuals. Some normal persons develop cancer as a result of bad luck; they are victims of spontaneous processes or background processes such as gene mutation or chromosomal rearrangement. Others are susceptible because they are exposed to environmental agents that increase these background rates. But there are individuals who are predisposed to cancer because they carry mutations that are already on the path to cancer or carry genes that increase the prospect that such mutation will occur, either spontaneously or in response to an environmental agent. It is even possible that most environmental cancer also involves genetic predisposition.

Overview: genes that predispose to cancer.

Heredity and environment both operate in the origin of cancer. Dominantly heritable cancer is caused by 'cancer' genes that impart high relative risks but account for only a small part of the incidence of cancer; they are usually recessive in oncogenesis, mutation or loss of the second allele being necessary. Non-hereditary forms of cancer may involve the same genes. Other genes interact with environment in carcinogenesis; these may impart relatively small relative risks, but because their frequencies may be high, the attributable risks can be great, as probably is the case with lung cancer. The process of carcinogenesis is thought to involve 2 or more somatic genetic events in most cases. The genes whose germline mutations cause dominantly inherited cancer can also be mutated somatically to cause non-hereditary cancer. Other genes may influence the numbers of target cells, or the proliferation of once-hit stem cells, without being critical events on the path to cancer. However, such genes could greatly influence the incidence of a cancer. Other genes, such as that for Bloom's syndrome, may affect the rates at which first and second events occur. Finally, other genes may influence the occurrence of events critical for progression and metastasis, such as vascularization of a small tumor.

Genetics of tumors of the head and neck.

Two uncommon tumors of the head and neck first revealed primary roles for two classes of cancer genes (oncogenes, tumor suppressor genes) in the origin of human cancer. In Burkitt's lymphoma the initiating event is a chromosomal translocation that leads to unregulated expression of an oncogene (MYCC), whereas retinoblastoma involves loss of function of both copies of a tumor suppressor gene (RB1). In osteosarcoma the RB1 gene is often affected, as is the gene (TP53) that codes for the p53 protein. TP53 is frequently mutated in carcinomas of the head and neck, as in one of the ras oncogenes. Multiple genetic changes typify carcinomas. Some carcinomas of the head and neck contain one of the human papilloma viruses that produce proteins that combine with and inactivate p53 and pRB proteins, rendering mutations in these genes unnecessary.

The genetics of childhood cancer.

Two classes of genes are apparently critical in the origin of the cancers of children. One class, that of oncogenes, acts by virtue of abnormal or elevated activity. It is operative primarily in leukemias and lymphomas. There is no evidence yet that genetic predisposition to these neoplasms can be imparted by oncogene mutations in the germline. However, there are conditions that predispose to these tumors, primarily through excessive chromosomal breakage and rearrangement. The other class, that of anti-oncogenes, is recessive in oncogenesis; cancer results when both normal copies have been mutated or deleted. Some persons carry one such mutation in the germline and are highly susceptible to tumor because only one somatic event is necessary. Some children, even though carrying no such mutation in the germline, can acquire tumor as a result of two somatic events. Most solid tumors in children seem to involve initiation through the loss of both copies of an anti-oncogene.